Evinacumab

Evinacumab (REGN1500) is a human anti-ANGPTL3 (angiopoietin-like protein 3) monoclonal antibody (IgG4 class antibody) . Evinacumab reduces plasma lipids in dyslipidemic mice by blocking ANGPTL3. Evinacumab can be used in studies of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolaemia (both familial and non-familial) and severe hypertriglyceridaemia[1].

Product Specifications

CAS Number

[1446419-85-7]

Product Name Alternative

REGN1500

UNSPSC

12352203

Target

ANGPTL

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/evinacumab.html

Purity

99.24

Solubility

10 mM in DMSO

Smiles

[Evinacumab]

Molecular Weight

(144.5 kDa)

References & Citations

[1]Gusarova V, et al. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys. J Lipid Res. 2015 Jul;56 (7) :1308-17.